BLUE Add to watchlist $4.97 +0.00 (+0.00%) Last updated: Apr 16, 2026 00:46
52-Week Range
$4.97
$3.98 $4.97 $5.96

Fundamentals Overview

bluebird bio, Inc. is in the middle of its 52-week range with low valuation, trading relatively flat today.

Valuation low

P/S 0.63

Risk (Beta)

0.37 — lower vol

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 41% confidence Risk: Lower Volatility — Beta 0.37. Diversify and only invest what you can afford to lose.

Supporting (Buy):

Sentiment improving (6 upgrades)

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$48.67M
P/E (TTM)
N/A
EPS (TTM)
N/A
Dividend Yield
N/A
52-Week Range
$3.98 - $5.96
Volume vs Avg
N/A
Beta
0.37

About

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and H...
Sector: Healthcare
Headquarters: US
Employees: 248
IPO Date: Jun 2013
Beta: 0.37 (Less volatile than market)

Ratings & Grades at a Glance

Recent institutional grades: majority upgrades. Current institutional positions: Buy: 5, Equal Weight: 5, Neutral: 4, Outperform: 3, Overweight: 6, Reduce: 1, Sector Perform: 3, Underweight: 3.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $-406.92; current price is $4.97. That’s a -8287.5% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) N/A
PEG (TTM) N/A
P/B (TTM) N/A
P/S (TTM) 0.63
Liquidity & enterprise
Current Ratio (TTM) 0.55
Quick Ratio (TTM) 0.29
Cash Ratio (TTM) 0.25
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) -74.81%
Gross margin (TTM) 54.65%
Operating margin (TTM) -79.07%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for BLUE.

Analyst Sentiment at a Glance

Sentiment Improving
Buy 5Equal Weight 5Neutral 4Outperform 3Overweight 6Reduce 1Sector Perform 3Underweight 3
6 upgrades, 2 downgrades
Price Target Consensus
Current $4.97
Median $12.50
Consensus $13.69
Low consensus $5.00
High consensus $25.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Barclays maintain Overweight Overweight 2025-03-31
JP Morgan upgrade Underweight Neutral 2025-02-24
Wells Fargo maintain Equal Weight Equal Weight 2025-02-24
Barclays maintain Overweight Overweight 2024-12-31
B of A Securities downgrade Buy Neutral 2024-11-15
RBC Capital maintain Sector Perform Sector Perform 2024-11-15
Barclays maintain Overweight Overweight 2024-11-15
Wells Fargo maintain Equal Weight Equal Weight 2024-09-25
B of A Securities maintain Buy Buy 2024-08-15
RBC Capital maintain Sector Perform Sector Perform 2024-08-15
Barclays maintain Overweight Overweight 2024-08-15
Baird maintain Outperform Outperform 2024-08-15
JP Morgan downgrade Overweight Neutral 2024-08-15
Wells Fargo maintain Equal Weight Equal Weight 2024-03-27
RBC Capital maintain Sector Perform Sector Perform 2024-03-27
Wedbush maintain Neutral Neutral 2024-03-19
HSBC maintain Reduce Reduce 2024-03-05
B of A Securities maintain Buy Buy 2023-12-21
Wells Fargo maintain Equal Weight Equal Weight 2023-12-15
Baird maintain Outperform Outperform 2023-12-12
B of A Securities maintain Buy Buy 2023-12-11
Morgan Stanley upgrade Underweight Equal Weight 2023-12-08
Raymond James maintain Outperform Outperform 2023-11-08
B of A Securities upgrade Neutral Buy 2023-07-19
B of A Securities upgrade Neutral Buy 2023-07-18
Morgan Stanley maintain Underweight Underweight 2023-07-11
Morgan Stanley maintain Underweight Underweight 2023-07-10
Barclays upgrade Equal Weight Overweight 2023-06-01
Barclays upgrade Equal Weight Overweight 2023-05-31
Morgan Stanley maintain Underweight Underweight 2023-04-03